# Daclizumab to Treat Wegener's Granulomatosis

> **NCT00040248** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 75 (—)

## Conditions studied

- Wegener's Granulomatosis

## Interventions

- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00040248
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 75 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040248, "Daclizumab to Treat Wegener's Granulomatosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00040248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*